C4 Therapeutics to present data from Phase 1 trial of cemsidomide

C4 Therapeutics (CCCC) announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma will be shared in an oral presentation at the International Myeloma Society Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada. C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM, which continues to demonstrate a well-tolerated safety profile and compelling response rates. The presentation at the IMS Annual Meeting will include data from all safety and efficacy evaluable MM patients from all dose levels studied in the cemsidomide with dexamethasone cohort in the Phase 1 trial. C4T’s investor webcast will highlight the data from the oral presentation at the IMS Annual Meeting and provide additional detail on the company’s planned next steps of clinical development.